Aberrant Overexpression of Pyruvate Kinase M2 Is Associated with Aggressive Tumor Features and the BRAF Mutation in Papillary Thyroid Cancer.

CONCLUSIONS:We conclude that overexpression of PKM2 provides a selective growth advantage for PTC cells through activation of glycolysis. Aberrant PKM2 overexpression may serve as a novel biomarker and a potential treatment target for PTC. The BRAF mutation may contribute to alterations in the expression pattern of glycolytic enzymes such as PKM2. PMID: 23846818 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/23846818?dopt=Abstract

Source: The Journal of Clinical Endocrinology and Metabolism - July 11, 2013 Category: Endocrinology Authors: Feng C, Gao Y, Wang C, Yu X, Zhang W, Guan H, Shan Z, Teng W Tags: J Clin Endocrinol Metab Source Type: research